Stocks · News reference
Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug
The FDA approved Takeda's MIMRYLO to treat erythrocytosis in adults with polycythemia vera, offering an effective new hematocrit control.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight
The ulcerative colitis market is experiencing significant growth with emerging therapies addressing unmet needs in moderate-to-severe disease. The market, valued at approximately USD 9.4 billion in 2025, is projected to expand at a CAGR of 7.6% through 2036. Five promising late-stage candidates—Obefazimod (Abivax), Tulisokibart (Merck), Afimkibart (Roche), Icotrokinra (J&J/Protagonist), and Duvakitug (Teva/Sanofi)—are reshaping the treatment landscape with novel mechanisms targeting IL-23 and TL1A pathways, while established biologics and oral therapies continue to maintain market presence.
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180
Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Cantor Fitzgerald raised
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - SNS Insider
The global Enzyme Replacement Therapy (ERT) market is projected to grow from USD 12.24 billion in 2025 to USD 27.90 billion by 2035, with a CAGR of 8.59%. Growth is driven by early identification of rare lysosomal storage disorders, increased newborn screening, orphan drug incentives, and expanding healthcare access. North America leads with 38.76% market share, while Asia-Pacific shows the fastest growth at 9.43% CAGR. Imiglucerase dominates products, and Gaucher disease represents the largest therapeutic condition.
AI in Drug Discovery Market Poised for Rapid Growth Through 2035, Fueled by Faster R&D, Precision Medicine and Rising Biopharma Investment
The global AI in drug discovery market is projected to grow from USD 2.55 billion in 2025 to USD 31.79 billion by 2035, expanding at a 28.70% CAGR. Lead optimization and oncology applications are driving adoption, with pharmaceutical companies and biotech firms leading investment. Strategic partnerships and funding rounds, including Isomorphic Labs' $600 million raise and Takeda's $1.7 billion collaboration with Iambic Therapeutics, are accelerating market growth.